Inhibiting HDACs in a preclinical model of HTLV-1-induced adult T-cell lymphoma

Leukemia Research

Volumn 35, Issue 11, 2011, Pages 1436-1437

  Harrod, Robert ^a  

^a SOUTHERN METHODIST UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AR 42; ARSENIC TRIOXIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTINOSTAT; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT; PREDNISOLONE; ROMIDEPSIN; UNCLASSIFIED DRUG; VALPROIC ACID; VINCRISTINE SULFATE; VORINOSTAT; ZIDOVUDINE;

ADULT; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; COGNITIVE DEFECT; CUTANEOUS T CELL LYMPHOMA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; ENZYME INHIBITION; GENE EXPRESSION; GENETIC TRANSFECTION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; LUNG SMALL CELL CANCER; LYMPHOCYTE TRANSFORMATION; MANTLE CELL LYMPHOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PSYCHOPATHY; RNA VIRUS INFECTION; SOLID TUMOR; SURVIVAL TIME; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE; VIRUS CELL INTERACTION;

ANIMALS; ENZYME INHIBITORS; FEMALE; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; PHENYLBUTYRATES;

EID: 84860405113     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.07.036     Document Type: Editorial

References (20)

1. Zimmerman B., Sargeant A., Landes K., Fernandez S.A., Chen C.S., Lairmore M.D. Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of human T-lymphotropic virus type 1 adult T cell lymphoma. Leuk Res 2011, 35:1491-1497.
2. Sargeant A.M., Rengel R.C., Kulp S.K., Klein R.D., Clinton S.K., Wang Y.C., et al. OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2008, 68:3999-4009.
3. Kulp S.K., Chen C.S., Wang D.S., Chen C.Y., Chen C.S. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res 2006, 12:5199-5206.
4. Nicot C., Harrod R.L., Ciminale V., Franchini G. Human T-cell leukemia/lymphoma virus type 1 nonstructural genes and their functions. Oncogene 2005, 24:6026-6034.
5. Van Prooyen N., Andresen V., Gold H., Bialuk I., Pise-Masison C., Franchini G. Hijacking the T-cell communication network by the human T-cell leukemia/lymphoma virus type 1 (HTLV-1) p12 and p8 proteins. Mol Aspects Med 2010, 31:333-343.
6. Zhang W., Nisbet J.W., Albrecht B., Ding W., Kashanchi F., Bartoe J.T., et al. Human T-lymphotropic virus type 1 p30(II) regulates gene transcription by binding CREB binding protein/p300. J Virol 2001, 75:9885-9895.
7. Nicot C., Dundr M., Johnson J.M., Fullen J.R., Alonzo N., Fukumoto R., et al. HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication. Nat Med 2004, 10:197-201.
8. Younis I., Boris-Lawrie K., Green P.L. Human T-cell leukemia virus open reading frame II encodes a posttranscriptional repressor that is recruited at the level of transcription. J Virol 2006, 80:181-191.
9. Clerc I., Polakowski N., Andre-Arpin C., Cook P., Barbeau B., Mesnard J.M., et al. An interaction between the human T cell leukemia virus type 1 basic leucine zipper factor (HBZ) and the KIX domain of p300/CBP contributes to the down-regulation of tax-dependent viral transcription by HBZ. J Biol Chem 2008, 283:23903-23913.
10. Andresen V., Pise-Masison C.A., Sinha-Datta U., Bellon M., Valeri V., Washington Parks R., et al. Suppression of HTLV-1 replication by Tax-mediated re-routing of the p13 viral protein to nuclear speckles. Blood 2011, [Epub ahead of print].
11. Choudhary G., Ratner L. The HTLV-1 hbz antisense gene indirectly promotes tax expression via down-regulation of p30(II) mRNA. Virology 2011, 410:307-315.
12. Nicot C., Harrod R. Distinct p300-responsive mechanisms promote caspase-dependent apoptosis by human T-cell lymphotropic virus type 1 Tax protein. Mol Cell Biol 2000, 20:8580-8589.
13. Awasthi S., Sharma A., Wong K., Zhang J., Matlock E.F., Rogers L., et al. A human T-cell lymphotropic virus type 1 enhancer of Myc transforming potential stabilizes Myc-TIP60 transcriptional interactions. Mol Cell Biol 2005, 25:6178-6198.
14. Anupam R., Datta A., Kesic M., Green-Church K., Shkriabai N., Kvaratskhelia M., et al. Human T-lymphotropic virus type 1 p30 interacts with REGgamma and modulates ATM (ataxia telangiectasia mutated) to promote cell survival. J Biol Chem 2011, 286:7661-7668.
15. Baydoun H.H., Pancewicz J., Nicot C. Human T-lymphotropic type 1 virus p30 inhibits homologous recombination and favors unfaithful DNA repair. Blood 2011, 117:5897-5906.
16. Jung K., Dasgupta A., Huang K., Jeong S.J., Pise-Masison C., Gurova K.V., et al. Small-molecule inhibitor which reactivates p53 in human T-cell leukemia virus type 1-transformed cells. J Virol 2008, 82:8537-8547.
17. Mori N., Matsuda T., Tadano M., Kinjo T., Yamada Y., Ysukasaki K., et al. Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. J Virol 2004, 78:4582-4590.
18. Jeong S.J., Radonovich M., Brady J.N., Pise-Masison C.A. HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity. Blood 2004, 104:1490-1497.
19. Hasegawa H., Yamada Y., Tsukasaki K., Mori N., Tsuruda K., Sasaki D., et al. LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway. Leukemia 2011, 25:575-587.
20. Nishioka C., Ikezoe T., Yang J., Komatsu N., Bandobashi K., Taniguchi A., et al. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB. Leuk Res 2008, 32:287-296.